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The Clustered Regions of Interspersed Palindromic Repeats-Cas9 (CRISPR/Cas9), a viral defense system found in
bacteria and archaea, has emerged as a tour de force genome editing tool. The CRISPR/Cas9 system is much easier
to customize and optimize because the site selection for DNA cleavage is guided by a short sequence of RNA rather than
an engineered protein as in the systems of zinc finger nucleases (ZFN), transcription activator–like effector
nucleases (TALEN), and meganucleases. Although it still suffers from some off-target effects, the CRISPR/Cas9
system has been broadly and successfully applied for biomedical discoveries in a number of areas. In this review, we
present a brief history and development of the CRISPR system and focus on the application of this genome editing
technology for biomedical discoveries. We then present concise concluding remarks and future directions for this fast
moving field.
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Targeted genome engineering provides the ability to pre-
cisely modify genetic information in order to study gene
function, biological mechanisms, and disease pathology.
Historically, random mutagenesis or low-efficiency homolo-
gous recombinations were used to modify the genomes of
cell lines or animal models. However, new advances in the
design of sequence-specific endonucleases have enabled
more effective, targeted editing of the genome.
The first prevalent method for targeted genome editing
utilizes zinc finger nucleases (ZFN) [1–3]. ZFN are proteins
capable of binding to specific regions of DNA. These nucle-
ases consist of a zinc finger protein bound to the cleavage
domain of the restriction enzyme FokI [4]. Meganucleases,
though not widely adapted, are restriction endonucleases
that bind larger than normal (12 bp) sequences of DNA
[5, 6]. Transcription activator–like effector nucleases
(TALENs) are engineered proteins with a sequence-
specific DNA-binding domain fused to a nonspecific
DNA-cleaving nuclease [7, 8]. Finally, the most recent
and fastest growing method for genome editing is based
on the Clustered Regions of Interspersed Palindromic* Correspondence: sqye@cmh.edu
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teria and archaea [9].
The common factor in all of these methods is the neces-
sity to introduce a double stranded break (DSB) in genomic
DNA. When DSBs occur naturally, cells respond by activat-
ing DNA repair machinery. Utilization of these repair pro-
cesses allows for either homology directed repair (HDR) or
non-homologous end joining (NHEJ) recombination result-
ing in the insertion, deletion, or mutation of specific DNA
sequences [10]. Thus, the ability to generate DSBs at tar-
geted genomic locations, coupled with DNA repair mecha-
nisms, has revolutionized genome editing.
The development of ZFN, TALEN, and to some extent
meganuclease, technologies requires the design of custom
endonucleases to target specific regions of DNA. Although
these methods have been used to edit genomes successfully,
there remain significant technical drawbacks. First, the
development of custom proteins for the recognition of spe-
cific DNA sequences is cumbersome and expensive. Sec-
ond, the optimization of these custom proteins is very time
consuming. In contrast, the CRISPR system is easy to
customize and optimize because the site selection for DNA
cleavage is guided by a short sequence of RNA rather than
an engineered protein. The short CRISPR RNA molecule
(crRNA), also called a guide RNA (gRNA), utilizes standard
Watson-Crick binding to recognize the target sequence,rticle distributed under the terms of the Creative Commons Attribution License
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nuclease (Cas) to create the DSB. This feature not only
makes it easy to develop targeted modifications of a single
gene, but it also facilitates the development of functional
genetic screens using libraries of gRNAs targeting thou-
sands of genes [11, 12]. In this review, we present a brief
history and development of the CRISPR system and focus
on the application of this genome editing technology for
biomedical discoveries followed by concluding remarks
with a look toward possible future directions for this popu-
lar technology.
History of CRISPR
Ishino et al. initially discovered the CRISPR architecture in
the 1980s when they noticed an “unusual structure” in the
3′ flanking region of the Escherichia coli iap gene [13]. The
region contained 5 highly homologous 29 base pair (bp)
nucleotide sequences separated by 32 bp nucleotide vari-
able regions. Over the next decade additional examples of
CRISPR loci were identified as more and more bacterial ge-
nomes were sequenced. The CRISPR acronym itself was
proposed in 2002 by Jansen and Mojica [14]. It wasn’t until
20 years after their initial discovery that the spacer se-
quences located within the CRISPR repeats were shown to
confer resistance to specific bacteriophage introduced to
the bacterial strain Streptococcus thermophilus, a commonly
used bacteria in the dairy industry [9]. These initial obser-
vations have since been confirmed in other organisms and
now, the unique spacer regions in the CRISPR loci are
understood to be a type of immune memory system to pro-
tect against invading phage or plasmid DNA. Through this
system the bacteria are able to extract a short sequence
from the invading DNA and file it away in the CRISPR
locus where it can be accessed later by transcription. Recent
work utilizing CRISPR/Cas loci deficient Staphylococcus
aureus transformed with the commonly used Streptococus
pyogenes CRISPR locus has shown that multiple cas genes
are important for the initial identification and excision of
invading DNA [15].
While the role of the Cas proteins is now better under-
stood, their role in CRISPR based resistance was originally
a mystery. Structural analysis of different Cas proteins iden-
tified homology to known endonuclease domains, suggest-
ing a possible role in conferring viral resistance through the
introduction of DSBs. During activation of the CRISPR re-
sponse the unique spacer sequences are transcribed into
short crRNAs. Garneau et al., was one of the first groups to
show crRNA worked with Cas proteins to lead to DSBs in
invading DNA [16]. The identification and characterization
of different cas genes in multiple bacteria and archaea lead
to the classification of three major CRISPR types (I, II
and III). The categorization of the cas genes was first pro-
posed by Haft et al. [17] and later updated by Makarova
et al. [18]. Evidence that Cas9 was an RNA guidedendonuclease with independent nuclease domains respon-
sible for cutting both strands of DNA was presented later
by Jinek et al. [19]. This was followed by the direct confirm-
ation of this interaction through the solving of the crystal
structure of the Cas9- guideRNA-target DNA complex
[20]. Since this discovery numerous labs have modified the
system to improve it by reducing off-site targeting [21] or
utilizing it for alternative goals such as affecting gene tran-
scription [22] or creating large libraries for functional
screens [11, 12].
Although there is great diversity in the CRISPR/Cas sys-
tems, they all share three common stages: adaptation,
crRNA biogenesis and immunity. Adaptation is the
process of acquiring unique spacer sequences from viral
and plasmid DNA. crRNA biogenesis involves the tran-
scription and processing of crRNA. Immunity, also termed
interference, entails the formation of an endonuclease
complex capable of recognizing and digesting invading
phage and plasmid DNA. The discovery of endonucleases
that could be guided to specific regions of the genome was
met with immediate interest. Successful attempts to de-
velop easy to use genome editing methods lead to the cre-
ation of chimeric RNA systems containing crRNA and the
trans activating RNA (tracrRNA) to create a single guide
RNA (sgRNA) to be used with the Cas protein, Cas9
[23, 24]. Since then researchers at the Broad Institute
of MIT and Harvard have been awarded a U.S. Patent
for the technology, which they have licensed to mul-
tiple biotechnology companies leading to a huge
growth in the technology and its availability. A sum-
mary of the history of CRISPR/Cas technological devel-
opment can be seen in Fig. 1.
CRISPR Types I and III
As an increasing number of bacteria and archaea were
found to contain CRISPR loci, different mechanisms of im-
munity, often times species specific, immerged. The
CRISPR locus is composed of unique pre-crRNA sequences
obtained from invading DNA inserted between a series of
direct repeats (~20-50 bp) [25, 26]. The pre-crRNA se-
quence is transcribed, processed into mature crRNAs, and
assembled into an interference complex with one or more
Cas proteins. The cas genes, which are organized as an op-
eron, are located upstream of the CRISPR locus promoter
and are important for both information processing and the
subsequent interference. The three main CRISPR types
consist of 10 subtypes; 5 type I, 3 type II and 2 type III
[27, 28]. The CRISPR/Cas systems differ in the organization
of cas genes into operons, as well as the nature of the re-
peats in the CRISPR array. These structural features dictate
how the pre-crRNA is processed, how the components of
the interference complex are assembled, whether there is
secondary processing of the complex, and how the interfer-
ence complex recognizes and cuts its target (Table 1). The
Fig. 1 History of CRISPR/Cas development. A useful understanding of the potential and capabilities of the CRISPR/Cas system took many years to
develop. Only recently has there been an explosion in the development and application of this system
Riordan et al. Cell & Bioscience  (2015) 5:33 Page 3 of 11type II system is the best understood of the three CRISPR
systems, due largely to the fact that only one Cas protein,
Cas9, is required for introducing DSBs [9]. The relative
simplicity of the type II system has lead to its adoption into
a ready-made tool for genome manipulation. Because this
review focuses on the current state of application of the
CRISPR/Cas9 system in basic and translational research,
we will not present detailed information about types I and
III. Those interested in these systems should read the re-
cent excellent review from Hochstrasser and Doudna [27].
CRISPR – Type II
The CRISPR system loci is defined by the presence of the
20 – 50 base pair repeats separated by the unique spacer
sequences acquired from invading viral and plasmid DNATable 1 Major components of each CRISPR typea
Action Type I
Spacer acquisition Cas1/Cas2
Pre-cRNAprocessing Cas6 or Cas5
Interference Complex members Cascade
Secondary processing None
Interference Subtubes I-A, I-B, I-E, I-F, I-C,
aCRISPR types are characterized by their operon composition the involved Cas prot
the defining characteristics of each type [27, 28]. Cascade = CRISPR-associated comp[29]. In the type II CRISPR system, spacer acquisition de-
pends on Cas1, Cas2, Csn2, and Cas9. While Csn2 and
Cas9 are unique to the type II system, Cas1 and Cas2 seem
to be common to all three CRISRP types [15, 18]. For the
type II system there is evidence that Cas9 is integral in the
initial recognition of the potential protospacer + PAM se-
quence in the invading DNA [15]. This dual role for Cas9
is a logical mechanism to ensure that the protospacers se-
lected will be present next to the required PAM sequence
so that Cas9 will be able to recognize it for future targeting
and cleavage when challenged. Following transcription,
RNAse III and Cas9 process the pre-crRNA transcript into
the mature crRNA forms [30]. In addition to processing the
pre-crRNA transcript, Cas9 also functions as the sole endo-




5′ end cleavage 3′ end cleavage
II-A, II-B, II-C III-A, III-B
eins and the structure of the repeats in the CRISPR array. This table presents
lex for antiviral defense
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after forming a complex with the crRNA and a tracrRNA.
TracrRNA forms a duplex with the crRNA and is essential
for the proper Cas9:crRNA interaction and recognition of
the target DNA sequence (Fig. 2) [30].
Cas9 cleavage depends upon the presence of a proto-
spacer adjacent motif (PAM) in the target DNA. PAM
recognition sequences can vary greatly between bacteria.
For genome engineering purposes, the most commonly
used Cas9, SpCas9, comes from Streptococcus pyogenes
[23]. SpCas9’s popularity is largely based on its short
PAM recognition sequence, 5′-NGG-3′ or at a lower
frequency, 5′-NAG-3′ [31] allowing for increased prob-
ability of having a potential protospacer located at the
desired location of the gDNA. However, additional
Cas9’s have been isolated from other bacteria and used
for CRISPR genome engineering. Examples of additional
tested Cas9s include NmCas9 and SaCas9 from Neis-
seria menigitidis and Staphylococcus aureus, respectively.
NmCas9’s PAM sequences are 5′-NNNNGATT-3′ or
5′-NNNNGCTT-3′. SaCas9’s PAM most efficient se-
quence is 5′-NNGRRT-3′ though all 5′-NNGRR-3′ can
be cleaved (R = A or G) [32, 33]. The smaller size of
SaCas9 is better suited for viral delivery than spCas9
and therefore, is especially advantageous for in vivo work
[33]. The PAM site must be located immediately 3′ of
the protospacer in the DNA for proper recognition by
the PAM binding domain in Cas9 [19, 34, 35]. Cas9 con-
tains two cleavage domains, HNH and RuvC, and each
is responsible for cleaving one strand of the DNA whenFig. 2 Mechanism of Cas9 action. a The three essential components necessary
tracrRNA. The introduction of the linker region to combine the crRNA and tracrR
b Recognition of the protospacer region by the sgRNA in conjunction w
cleavage. c Cleaved DNA fragments. d Mutated forms of Cas9 can cont
one strand of the DNA is cleaved. e Alternatively both catalytic domain
be tethered to effector molecules to target repression or activation, KRAB and Vbound (Fig. 2b) [19]. The PAM sequence is necessary for
both initial protospacer acquisition and for later interfer-
ence. The PAM requirement increases the specificity of
the guidance system and blocks the ability of the com-
plex to cut the CRISPR loci.
Development of CRISPR Cas9 for molecular biology
Once the necessary components for RNA guided endonu-
culease activity were determined, the race was on for the
development of these components into a customizable sys-
tem for the introduction of targeted DSBs into the genomes
of various organisms. The use of the Cas9 system for gen-
etic alteration centers on the repair mechanism that is initi-
ated by the introduction of the DSB by Cas9. When DSBs
occur in the genome the breaks can be repaired along two
possible pathways, NHEJ and HDR. The first pathway,
NHEJ, involves the quick ligation of the blunt ends of DNA
remaining after DSBs occur. There are two subtypes of
NHEJ, canonical and alternative end joining [36]. The ca-
nonical pathway results in relatively few errors or small de-
letions. However, if this pathway fails, the more error prone
Ligase I or Ligase III-dependent end joining will take over
and will likely lead to one or more of a variety of mutations.
These random mutations can cause insertions or deletions
(indels) that could alter open reading frames and insert pre-
mature stop signals resulting in a gene knockout.
The second pathway, HDR, normally uses a sister chro-
matid as a homologous template to repair DNA damage. In
eukaryotic cells the occurrence of HDR is extremely low, in
part due to the much more prevalent NHEJ. For genomefor CRISPR/Cas activity, using spCas9 as an example, are Cas9, crRNA and
NA into a single guide RNA (sgRNA) improves overall targeting efficiency.
ith Cas9 recognition of the appropriate PAM sequence initiates
ain a single active domain to act as a Cas9n “nickase” where only
s can be mutated to form a dCas9 “dead” nuclease that can then
P64 respectively, for example. Images adapted from motifolio.com
Table 2 Summary of CRISPR/Cas9 applications
The original application of the CRISPR/Cas, Genome Engineering, has
proven to be extremely useful in the investigation of numerous genetic
features and the improved creation of transgenic animals. However, the
modification of the Cas protein has lead to the development of additional
applications including: gene Activation and Repression through the
use of effector molecules tethered to inactive Cas9, Functional
Screening through libraries of guide RNAs to introduce NHEJ
based InDels or through activation/repression dCas9, Inducible
Regulation through the use light or chemical induction for more
specific control, DNA labeling through fluorescently labeled dCas9,
Isolation of specific genomic regions through epitope labeled
dCas9 and finally the ability to introduce multiple sgRNAs and or
various Cas9 proteins with different PAM site requirements allows for
more complicated Multiplexing experimental designs. The power
of these various applications is enhanced by their utility both in vitro
and in vivo as these techniques have been shown to be effective in a wide
variety of cell lines and animal models
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introducing custom template DNA containing homologous
arms on either side of a DSB site. This technique can be
used to insert novel DNA or remove portions of the gen-
ome allowing for a multitude of custom changes, including
gene insertion, gene deletion, gene mutation, promoter ac-
tivation or suppression, SNP alteration, and others [37, 38].
To increase the efficiency of HDR for use with CRISPR, re-
searchers have suppressed a number of key factors in the
NHEJ pathway, which has lead to 4 – 8 fold higher effi-
ciency of HDR in mammalian cells [39]. For those looking
for more information on HDR, an excellent review by
Heyer et al. can be found here [40].
The specific nature of CRISPR/Cas9 allows for mul-
tiple genes to be targeted and repaired simultaneously.
CRISPR multiplexing was first performed in vitro with
individual plasmids, but can now be accomplished more
conveniently with a single plasmid containing multiple
sgRNAs [41]. Additional groups are working on harnes-
sing the CRISPR array system in E. coli for easier multi-
plexing [42]. Recently, Ma et al. simultaneously mutated
four different genes in vivo [43]. Additional systems
shown to be capable of CRISPR multiplexing include:
bacteria [44], plants [45], yeast, [46] pigs [47], frogs [48]
and zebra fish [49, 50]. For diseases where there can be one
or more mutations, such as Duchenne muscular dystrophy
(DMD), the ability to introduce multiple sgRNAs simultan-
eously has proven to be an effective strategy [51].
Shortcomings of CRISPR Cas9
While the ability to use a gRNA to actively target a region
of the genome for the introduction of a DSB is a huge ac-
complishment, this technology is not without its shortcom-
ings. The first of these shortcomings is the requirement of
a PAM sequence for the proper recognition of a target site
by the gRNA. While this requirement does increase the
specificity of the system, it has also decreased the flexibility
in the design of gRNAs for the purpose of genome editing.
However, the PAM site varies in both length and complex-
ity, depending on the CRISPR type and species, allowing
for increased flexibility in gRNA design [52]. In addition, if
the donor sequence to be used for HDR contains both the
full target site and the PAM site, then the efficiency of
HDR could suffer as the donor sequence would also be tar-
geted along with the genomic DNA [53]. The most com-
mon method to avoid this problem is to introduce silent
point mutations in the PAM site within the donor sequence
so that it will no longer be recognized. However, this solu-
tion does not allow for situations where point mutations
cannot be tolerated, such as when point mutations them-
selves are being studied for their effects on a promoter’s
transcription enhancement capabilities. In this instance
additional point mutations could cause unforeseen effects
on the binding of transcription factors to the DNA.The second shortcoming of the CRISPR Cas9 system
is the presence of unintended or “off-target” effects of
the gRNA. Because DSBs can lead to the introduction of
indels through the process of NHEJ, off-target effects
have the potential to introduce secondary and potentially
harmful mutations, which could possibly cause either a
reduction or increase in the production of a crucial gene.
Strategies, such as improving algorithms for gRNA de-
sign and using paired Cas9 nickases (Cas9n), where one
of the catalytic domains are inactivated to increase DSB
specificity, have proven effective in reducing off-target
effects to very low or even undetectable levels [23].
An alternative strategy to using nickases to reduce off-
target effects is through the use of a “dead” Cas9 (dCas9)
where both catalytic domains are inactivated [22]. While
dCas9 no longer has the ability to cleave, it can still
complex with the gRNA and bind to DNA, and as such,
it has proved to be an extremely useful molecular tool
for targeting other types of proteins to a specific region
of DNA. This modification has provided an additional
method for reducing off-target affects through the fusion
of the FokI catalytic domain to dCas9 (fCas9) [54, 55].
FokI is the same catalytic domain used in the ZFN and
TALEN systems of genome engineering. Similar to Cas9n,
fCas9 requires two separate guide RNAs to simultaneously
bind to one strand of DNA create a DSB and showed a
similar increase in specificity with Cas9n over wild type
Cas9. In addition, the use of the FokI domain should reduce
unintended modifications because of the more rigid spatial
requirements for cutting and the lack of activity as a mono-
mer that can occur with Cas9n.
Applications of the CRISPR/Cas9 system
The CRISPR/Cas9 system has emerged as a tour de force
genome editing tool. It has been broadly and successfully
applied for biomedical discoveries in a number of areas, a
summary of which can be seen in Table 2. The following
section is not intended to comprehensively catalog the full
Riordan et al. Cell & Bioscience  (2015) 5:33 Page 6 of 11spectrum of its applications but highlight several major ex-
amples of such rendering.
CRISPR/Cas9 regulation (as an alternative to RNAi)
One interesting repurposing of the CRISPR/Cas9 tech-
nology has been through modulation of the transcription
of various genetic targets. Current methods for tran-
scriptional repression and activation such as RNAi and
other DNA binding proteins, ZFN and TALEN, har-
bored significant shortcomings such as off-target effects,
toxicity, and in the case of ZFN and TALEN proteins,
difficulty with design and implementation. One of the
first attempts at CRISPR/Cas9 based interference was
with dCas9. dCas9 is useful because, though it is catalyt-
ically inactive it can still successfully target DNA. When
researchers targeted the promoter region of a gene of
interest it could cause between 100 and 300 fold repres-
sion in E. coli [22, 56], presumably through blocking the
binding of RNA polymerase due to steric hindrance.
This CRISPR based interference (CRISPRi) not only
showed high levels of repression but also no evidence of
off-target effects by RNA-seq. Interestingly, multiple
gRNAs targeting the same gene that were simultan-
eously introduced had a combinatorial effect on repres-
sion and could increase the level of knockdown to
nearly 1000-fold [56]. In the mammalian HEK cell line
the effect was not as potent as these cells showed at
most about a 2-fold expression difference and had a sig-
nificant number of sgRNAs that showed no effect at all
[56]. In addition to repression these first studies also ex-
plored the role that dCas9 could play in activation
(CRISPRa) by introducing a dCas9 fused to the RNA
polymerase ω subunit capable of causing up to 23-fold
increase in expression [22]. Alternatively, a tetramer of
the herpes simplex activation domain VP16, termed
VP64, has been shown to be effective activation inducing
effector molecule when tethered to dCas9 [57]. The
Zhang lab has optimized the use of VP64 for activation
through modification of both the sgRNA design and
addition of additional helper molecules, MS2, P65 and
HSF1, to create a new system called the synergistic acti-
vation mediator (SAM) [58].
Follow up studies on CRISPRi showed that the fusion of
repressor effector proteins such as the KRAB (Kruppel-
associated box) domain of Kox1 to dCas9 could increase
the effectiveness of repression of reporter gene activity
[59]. CRISPRi was also shown to be effective at repressing
microRNA in murine cells [60]. Further study of the abil-
ity of effector proteins bound to dCas9 to alter genes re-
lated to ricin resistance has lead to a better understanding
of the rules governing both CRISPRa and CRISPRi repres-
sion, leading to the development of a CRISPRi/CRISPRa
library screening system [61]. This system has several
advantages over other indel inducing CRISPR based loss-of-function library systems. As an inducible and reversible,
genome scale-screening platform without detectable in-
trinsic toxicity the CRISPRi/a system should prove to be
an important tool for many areas of research moving for-
ward [61].
CRISPR/Cas9 for improved creation of animal models
The characterization of disease phenotypes is a major
goal of mouse geneticists. Analyzing genetic mutations
in a whole animal may support and validate results
found in cell culture. Since the first transgenic mice
were made in 1981, the process has been improved,
resulting in a more versatile and user-friendly method.
The introduction of Bacterial Artificial Chromosomes
(BAC) in the 1990s allowed for the use of larger con-
structs. Traditional methods to create mouse models
with an altered genetic makeup can take from 8 to
13 months of work, which is a considerable investment
of both time and resources. By comparison, CRISPR/
Cas9 was used to create transgenic mice with an observ-
able albino phenotype after a single microinjection of
C57BL/6 J mouse embryos [62].
Seminal work by the Huang group showed that genetic
engineering in eukaryotes was possible by microinjection
of CRISPR/Cas9 mRNAs into zebrafish embryos. They
then took this a step further by showing that this tech-
nique could be used to delete a portion of EGFP in an
established transgenic mouse [63]. Since this initial proof
of concept experiment, numerous groups have contin-
ued to advance the field of transgenic mouse models
created by CRISPR/Cas9. Wang et al. showed that multi-
plexed targeting of numerous genes simultaneously
could create a complex mouse model in with a single in-
jection [64]. Wu et al. was one of the first groups to
show that it was possible to correct a genetic disease
in vivo when they rescued a cataract phenotype by cor-
recting a mutated Crygc gene [65]. In addition, CRISPR/
Cas9 can be used to delete up to 10 kb of the genome
via only 2 gRNAs [66]. Mutated Cas9n nickases have
also been shown to effectively facilitate the creation of
both knock-in and knock out mouse models with the
added benefit of reduced levels of off-target effects [67].
Another problem that researchers often have to deal with
is the production of recessive homozygous loss-of-function
mutations. To that end Gantz and Bier developed an auto-
catalytic mutation system they call mutagenic chain reac-
tion (MCR) [68]. MCR consists of a vector where Cas9 and
sgRNA are flanked by two homology arms targeting the re-
gion to be cut. This system was capable of effectively dis-
tributing itself in both somatic and germline cells in
Drosophila for the creation of homologous mutant flies that
would normally have not been possible by mendellian in-
heritance. MCR could prove to be extremely useful though
the authors do note that because of its ability to act
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animals were accidentally released into the environment.
They recommend strict barrier containment protocols and
increased dialogue within the scientific community about
the safety measures necessary for these types of tools [68].
Inducible CRISPR control
While editing or modifying the expression of particular re-
gions of an organism’s genome in every tissue and cell may
be a strategy for some basic and therapeutic applications of
RNA guided genome editing, there are situations where
these changes would need to be controlled more directly.
For example, doxycycline inducible CRISPR (iCRISPR) has
been developed to allow for genome targeting at later stages
of mouse development. This technology allows for the limi-
tation of the duration of Cas9 expression in a biallellic mu-
tation in multiple target loci [69]. Work in Feng Zhang’s lab
at the Broad Institute established that light controlled, re-
versible, genome activation was possible through the use of
a two hybrid TALEN system they termed light inducible
transcriptional effectors (LITES) [70]. Though this optoge-
netic system is effective it does not allow the same flexibility
in targeting as the newly developed light-activated CRISPR-
Cas9 effector system (LACE) [71]. Both of these systems
use blue light and the activator proteins cytochrome 2p
with its interacting partner CIB1 to accomplish activation
with LACE utilizing the inactive dCas9 protein. The ease
with which the LACE system can be redesigned allows for
use in difficult systems, such as those where multiple ef-
fector regions in a promoter need to be targeted. Through
the development of this system researchers found they
could increase the overall activation of a gene by including
multiple gRNAs targeting the promoter and by fusing the
N terminal fragment of CIB1 (CIBN) to both the 5′ and 3′
end of dCas9. Fusing to both ends of dCas9 resulted in
a 10 – 100 fold increase in activation compared to the
single fusion version [71].
CRISPR/Cas9 for SNP analysis in vivo
The first group to analyze individual point mutations with
CRISPR/Cas9 in vivo was the Takada group in Tokyo, Japan
[72]. The time and cost limitations of creating a mouse be-
fore CRISPR initially prevented the in vivo investigation of
SNPs. This limitation means that the majority of the work
done in this field has not been sufficiently validated. The
Takada group was able to show that by microinjecting syn-
thesized RNAs and single-strand oligodeoxynucleotide
(ssODN) as a donor template for HDR into mouse zygotes
they could introduce defined point mutations in the mouse
genome [72]. This technique could be used to study the
role of SNPs in other non-coding regions of the genome,
such as a transcription factor binding sites in a promoter or
a distal enhancer region. However, the wild type Cas9
showed some off-target effects, so the researchers used thehCas9 D10A nickase along with variously placed ssODNs.
Interestingly, they found that even though they were able to
successfully introduce the desired point mutation, HDR
was only able to incorporate the portion of the donor se-
quence that was in close proximity to the DSB site [72].
Additional animal models being developed
In addition to the large number of mouse models being
created with CRISPR/Cas9 technology, additional or-
ganisms have proven responsive to this method of manipu-
lation, including traditional animal models: Drosophila
melanogaster [73, 74], Caenorhabditis elegans [75, 76], Sac-
charomyces cerevisiae [77] and Dani rerio [78, 79].
CRISPR/Cas9 genetic engineering has also proven to be
possible in rats whose limited genetic toolbox was a large
reason to avoid this commonly used model organism
[80, 81]. In rats, multi-gene targeting and conditional
allele modifications have been performed successfully
in the generation of new transgenic models [82, 43].
Importantly, CRISPR/Cas9 technology is also proven to
be effective in non-traditional animal models, like goats
and pigs, which are important for both agricultural and bio-
medical research and development [83–88]. This technol-
ogy has even allowed for simplified genetic modification
[89] and creation of disease models [90] in non-human pri-
mates. These results indicate the potential of CRISPR/Cas9
to greatly improve our ability to model diseases in animals
more closely related to humans. Another interesting ex-
ample of how this technology is opening new avenues of re-
search can be seen in the development of a new animal
model, the short-lived African turquoise killifish Notho-
branchius furzeri. The killifish is an attractive alternative to
other vertebrate models used for age-related diseases such
as rodents or zebrafish. The shorter lifespan (4 – 6 months)
allows for an overall reduction in the time necessary for the
manifestation of an overt aging phenotype that includes
common aging biomarkers [91]. In addition, the killifish
has practical advantages such as lower maintenance costs
and the rapid production of offspring. When these advan-
tages are coupled with the ability to manipulate the genome
through CRISPR/Cas9 the potential for discovery in age-
related diseases is significantly enhanced [92].
Screening studies with CRISPR
Pioneering works from multiple groups lead to the rapid
production of pooled sgRNA libraries with the ability to
alter gene production for the purpose of screening cell lines
through either a positive or negative toxicity screen. These
techniques either induce random indels that will likely lead
to the disruption of a gene product, available in both
humans [11, 12, 93] and mice [94], or through inactive
dCas9 coupled to either repressors or activators [58, 61].
Chen et al. used a CRISPR screen to identify novel tumor
suppressor genes in an in vivo mouse cancer model, while
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porter system to identify the genes, CLDN1, OCLN and
CD81 as essential for both cell to cell transmission and cell
free entry [95, 96]. For a comprehensive look at the current
capabilities of genome wide screens please see the recent
review from Shalem et al. [97].
CRISPR/Cas9 as a potential therapeutic
One of the most exciting possibilities for the application
of this technology is in the field of gene therapy for the
treatment of diseases with a Mendelian genetic mutation
as the root cause. Duchenne muscular dystrophy (DMD)
is caused by mutations in the dystrophin gene, which
consists of 79 exons, located on the X chromosome,
making it a potential candidate for gene therapy [98].
Researchers from the Hotta group at Kyoto University,
Japan, have shown that exon knock-in in DMD-patient-
derived cells was the most effective way to correct muta-
tions in the dystrophin gene, compared to exon skipping
and frameshifting technologies. After correcting the vari-
ous mutations, they were able to differentiate the cor-
rected iPSCs into skeletal muscle cells that expressed
the full-length dystrophin gene [99]. CRISPR/Cas9 was
also effective in preventing the DMD phenotype in a
mouse model [100]. In addition, the recent creation of a
DMD disease model in the rhesus monkey using
CRISPR/Cas9 could lead to new therapeutic approaches
for this disease [90].
The CRISPR system, which has been adapted for numer-
ous uses, is based on a protozoan defense system against
viral infection, and therefore, it is a natural progression to
co-opt this system as an anti-viral therapeutic. One ex-
ample is the targeting of Hepatitis B virus. While current
technologies are able to inhibit the covalently closed circu-
lar viral DNA template, they are not able to destroy it.
However, Zhen et al. were able to target the surface antigen
of HBV specifically to reduce the amount of antigen se-
creted in both cell culture and mouse serum, and almost
completely eliminate its presence in mouse liver tissue
[101]. In addition to work on HBV, CRISPR/Cas9 was also
able to disrupt latent HIV infection in induced pluripotent
stem cells and protect against new HIV infection as a proof
of concept for the use of this technology as a treatment/
defense application [102].
While the aforementioned studies have shown that
CRISPR/Cas9 can be used to correct genetic maladies as
a proof of concept, treatment would need to be delivered
to developed individuals rather than at the embryonic
stage, as is the case for the creation of transgenic mice.
One of the first groups to show that genetic modifica-
tions could be made in adult animals was the Anderson
lab at MIT. They were able to show that a hydrodynamic
injection of CRISPR/Cas9 components could correct a
mutation in the Fah gene in the hepatocytes of atransgenic mouse model of human tyrosinemia [103].
In addition to these results, the Chiarle lab at Harvard
University used intratracheal and intrapulmonary deliv-
ery of CRISPR/Cas9 lentiviral vectors in adult male
mice to cause a chromosomal rearrangement of the
EML4 and Alk genes in order to mimic the inversion
responsible for creating the desired EML4-ALK fusion
protein. The engineered EML4-Akl gene fusion re-
sulted in lung tumors within two months after the
introduction of the recombinant virus [104]. These re-
sults indicate that genome editing in adult animals is
indeed possible with CRISPR/Cas9.
Additional uses of CRISPR/Cas9
The advent of CRISPR/cas9 has improved our ability to
study more difficult areas of genetics, such as epigenet-
ics. The use of dCas9 with epigenetic effector or repres-
sor molecules is an area of research that was largely
observational and can now move into a more experi-
mental form of research with loss-of-function and gain-
of-function studies now more possible than ever before
[105]. Another interesting use of CRISPR/Cas9 is the in-
vestigation of a specific genomic region. Visualization of
specific regions of DNA to better understand their spa-
tiotemporal organization can be accomplished through
fusing dCas9 to fluorescent protein such as EGFP [106].
This technique has recently been expanded to allow for
multicolor applications [107]. Identification of the proteins
bound to certain regions of the genome can be difficult but
the engineered DNA-binding molecule-mediated chroma-
tin immunoprecipitation method (enCHIP) developed by
the Fuji lab was able to use the dCas9 fused to a pro-
tein tag to purify specific regions of the genome [108].
Utilizing mass spectrometry, they were able to identify
the proteins associated with the immunoprecipitated
regions of chromatin.
Concluding remarks and future directions
Perhaps the ultimate goal of RNA guided genome edit-
ing is the development of therapies for both monogenic
and polygenic diseases. The biggest roadblock in the de-
velopment of these technologies is the issue of safety. It
has been shown that the CRISPR/Cas9 technology can
create the necessary changes to correct certain genetic
defects in cells cultured from diseased individuals. How-
ever, it is not clear what the systemic effects of the treat-
ment would be when administered to an individual.
Therefore, the next step in the development of these
treatments will be corresponding advances in methods
to ensure that only the diseased cells of interest would
be able to express the CRISPR/Cas components. Evidence
of this possibility has been published recently in zebrafish
[109]. Moreover, the issue of off-target effects still looms
large as a source of considerable apprehension about the
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ever, the development of nickases and advanced screening
via next generation sequencing has helped decrease the
likelihood of negative effects due to off-target effects. An-
other area where this system could be improved is in multi-
plex implementation. The Frew lab at the University of
Zurich has attempted to simplify and optimize this ap-
proach through the development of their multiple lentiviral
expression system (MuLE) that works as a modular vector
system for easy editing of multiple areas at once [110].
The CRISPR/Cas9 system of genome editing and ma-
nipulation has proved to be an exciting new development
for the fields of molecular biology and translational medi-
cine. The ability to use RNA guided endonucleases to target
virtually any area of an organism’s genome has lead to sig-
nificant improvements in our ability to study various
aspects of the genome, including the importance and func-
tion of the genes themselves, as well as the regulatory com-
ponents that control them. This technology has shown the
potential to bring about a new age of gene therapy that
could lead to the treatment of diseases that were previously
thought untreatable.Abbreviations
BAC: Bacterial artificial chromosome; Cas: CRISPR-associated proteins;
Cas9: Native Cas9 nuclease; Cas9n: Cas9 nickase (containing only one
functional catalytic domain); CIBN: Calcium and integrin-binding protein 1 N
terminal fragment; CRISPR: Clustered, regularly interspaced short palindromic
repeats; CRISPRa: CRISPR activation; CRISPRi: CRISPR inhibition; CRISPRi/
a: CRISPR inhibition and activation system; crRNA: CRISPR RNA; dCas9: “Dead”
Cas9 (containing no functional catalytic domains); DMD: Duchenne muscular
dystrophy; DSB: Double stranded break; enCHIP: Engineered DNA-binding
molecule mediated chromatin immunoprecipitation; fCas9: dCas9 fused to
FokI catalytic domain; gRNA: Guide RNA; HDR: Homology directed repair;
iCRISPR: Inducible CRISPR; KRAB: Kruppel-associated box domain of kox1;
LACE: Light-activated CRISPR-Cas9 effector system; LITES: Light inducible
transcriptional effectors; MCR: Mutagenic chain reaction; MULE: Multiple
lentiviral expression system; NHEJ: Non-homologous end joining;
NmCas9: Cas9 from Neisseria menigitidis; PAM: Protospacer adjacent motif;
SaCas9: Cas9 from Staphylococcus aureus; sgRNA: Single guide RNA;
SpCas9: Cas9 from Streptococcus pyogenes; ssODN: Single-strand
oligodeoxynucleotide; TALEN: Transcription activator-like effector nuclease;
tracrRNA: Trans-activating RNA; ZFN: Zinc finger nuclease.Competing interests
The authors declare that they have no competing interests.Authors’ contributions
SR planned, drafted and critically revised the manuscript, LZ critically revised
the manuscript, DH and SY planned and critically revised the manuscript. All
authors read and approved the final manuscript.Acknowledgements
Our research undertakings including a work in progress with the CRISPR-
CAS9 system have been in part supported by National Institutes of Health
Grant HL 080042 (Ye, S. Q.), the start-up fund and William R. Brown/ Missouri
Endowment of The Children’s Mercy Hospital and University of Missouri at
Kansas City (Ye, S.Q.).
Received: 15 April 2015 Accepted: 13 June 2015References
1. Bibikova M, Carroll D, Segal DJ, Trautman JK, Smith J, Kim YG, et al. Stimulation of
homologous recombination through targeted cleavage by chimeric nucleases.
Mol Cell Biol. 2001;21(1):289–97. doi:10.1128/mcb.21.1.289-297.2001.
2. Urnov FD, Miller JC, Lee YL, Beausejour CM, Rock JM, Augustus S, et al.
Highly efficient endogenous human gene correction using designed zinc-finger
nucleases. Nature. 2005;435(7042):646–51. doi:10.1038/nature03556.
3. Durai S, Mani M, Kandavelou K, Wu J, Porteus MH, Chandrasegaran S. Zinc
finger nucleases: custom-designed molecular scissors for genome engineering
of plant and mammalian cells. Nucleic Acids Res. 2005;33(18):5978–90.
doi:10.1093/nar/gki912.
4. Kim YG, Cha J, Chandrasegaran S. Hybrid restriction enzymes: zinc finger
fusions to Fok I cleavage domain. Proc Natl Acad Sci. 1996;93(3):1156–60.
5. Rouet P, Smih F, Jasin M. Introduction of double-strand breaks into the
genome of mouse cells by expression of a rare-cutting endonuclease. Mol
Cell Biol. 1994;14(12):8096–106.
6. Pâques F, Duchateau P. Meganucleases and DNA double-strand break-induced
recombination: perspectives for gene therapy. Curr Gene Ther. 2007;7(1):49–66.
7. Boch J, Scholze H, Schornack S, Landgraf A, Hahn S, Kay S, et al. Breaking
the code of DNA binding specificity of TAL-type III effectors. Science.
2009;326(5959):1509–12. doi:10.1126/science.1178811.
8. Christian M, Cermak T, Doyle EL, Schmidt C, Zhang F, Hummel A, et al.
Targeting DNA Double-Strand Breaks with TAL Effector Nucleases. Genetics.
2010;186(2):757–61. doi:10.1534/genetics.110.120717.
9. Barrangou R, Fremaux C, Deveau H, Richards M, Boyaval P, Moineau S, et al.
CRISPR provides acquired resistance against viruses in prokaryotes. Science.
2007;315(5819):1709–12. doi:10.1126/science.1138140.
10. Capecchi MR. Altering the genome by homologous recombination. Science.
1989;244(4910):1288–92.
11. Shalem O, Sanjana NE, Hartenian E, Shi X, Scott DA, Mikkelsen TS, et al.
Genome-scale CRISPR-Cas9 knockout screening in human cells. Science.
2014;343(6166):84–7. doi:10.1126/science.1247005.
12. Wang T, Wei JJ, Sabatini DM, Lander ES. Genetic screens in human cells using the
CRISPR-Cas9 system. Science. 2014;343(6166):80–4. doi:10.1126/science.1246981.
13. Ishino Y, Shinagawa H, Makino K, Amemura M, Nakata A. Nucleotide
sequence of the iap gene, responsible for alkaline phosphatase isozyme
conversion in Escherichia coli, and identification of the gene product.
J Bacteriol. 1987;169(12):5429–33.
14. Jansen R, Embden JDA, Gaastra W, Schouls LM. Identification of genes that are
associated with DNA repeats in prokaryotes. Mol Microbiol. 2002;43(6):1565–75.
15. Heler R, Samai P, Modell JW, Weiner C, Goldberg GW, Bikard D, et al. Cas9
specifies functional viral targets during CRISPR-Cas adaptation. Nature.
2015;519(7542):199–202. doi:10.1038/nature14245.
16. Garneau JE, Dupuis M-È, Villion M, Romero DA, Barrangou R, Boyaval P, et al.
The CRISPR/Cas bacterial immune system cleaves bacteriophage and
plasmid DNA. Nature. 2010;468(7320):67–71. doi:10.1038/nature09523.
17. Haft DH, Selengut J, Mongodin EF, Nelson KE. A guild of 45 CRISPR-associated
(Cas) protein families and multiple CRISPR/Cas subtypes exist in prokaryotic
genomes. PLoS Comput Biol. 2005;1(6):e60. doi:10.1371/journal.pcbi.0010060.
18. Makarova KS, Haft DH, Barrangou R, Brouns SJJ, Charpentier E, Horvath P,
et al. Evolution and classification of the CRISPR-Cas systems. Nat Rev
Microbiol. 2011;9(6):467–77. doi:10.1038/nrmicro2577.
19. Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier E. A
programmable dual-RNA-guided DNA endonuclease in adaptive bacterial
immunity. Science. 2012;337(6096):816–21. doi:10.1126/science.1225829.
20. Nishimasu H, Ran FA, Hsu PD, Konermann S, Shehata SI, Dohmae N, et al.
Crystal structure of Cas9 in complex with guide RNA and target DNA. Cell.
2014;156(5):935–49. doi:10.1016/j.cell.2014.02.001.
21. Ran FA, Hsu PD, Lin CY, Gootenberg JS, Konermann S, Trevino AE, et al.
Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing
specificity. Cell. 2013;154(6):1380–9. doi:10.1016/j.cell.2013.08.021.
22. Bikard D, Jiang W, Samai P, Hochschild A, Zhang F, Marraffini LA.
Programmable repression and activation of bacterial gene expression using
an engineered CRISPR-Cas system. Nucleic Acids Res. 2013;41(15):7429–37.
doi:10.1093/nar/gkt520.
23. Cong L, Ran FA, Cox D, Lin S, Barretto R, Habib N, et al. Multiplex genome
engineering using CRISPR/Cas systems. Science. 2013;339(6121):819–23.
doi:10.1126/science.1231143.
24. Mali P, Yang L, Esvelt KM, Aach J, Guell M, DiCarlo JE, et al. RNA-guided
human genome engineering via Cas9. Science. 2013;339(6121):823–6.
doi:10.1126/science.1232033.
Riordan et al. Cell & Bioscience  (2015) 5:33 Page 10 of 1125. Makarova K, Grishin N, Shabalina S, Wolf Y, Koonin E. A putative RNA-interference-
based immune system in prokaryotes: computational analysis of the predicted
enzymatic machinery, functional analogies with eukaryotic RNAi, and hypothetical
mechanisms of action. Biol Direct. 2006;1(1):7.
26. Kunin V, Sorek R, Hugenholtz P. Evolutionary conservation of sequence and
secondary structures in CRISPR repeats. Genome Biol. 2007;8(4):R61.
27. Hochstrasser ML, Doudna JA. Cutting it close: CRISPR-associated
endoribonuclease structure and function. Trends Biochem Sci.
2015;40(1):58–66. doi:10.1016/j.tibs.2014.10.007.
28. Chylinski K, Makarova KS, Charpentier E, Koonin EV. Classification and
evolution of type II CRISPR-Cas systems. Nucleic Acids Res.
2014;42(10):6091–105. doi:10.1093/nar/gku241.
29. Rousseau C, Gonnet M, Le Romancer M, Nicolas J. CRISPI: a CRISPR interactive
database. Bioinformatics. 2009;25(24):3317–8. doi:10.1093/bioinformatics/btp586.
30. Deltcheva E, Chylinski K, Sharma CM, Gonzales K, Chao Y, Pirzada ZA, et al.
CRISPR RNA maturation by trans-encoded small RNA and host factor RNase
III. Nature. 2011;471(7340):602–7. doi:10.1038/nature09886.
31. Jiang W, Bikard D, Cox D, Zhang F, Marraffini LA. CRISPR-assisted editing of
bacterial genomes. Nat Biotechnol. 2013;31(3):233–9. doi:10.1038/nbt.2508.
32. Hou Z, Zhang Y, Propson NE, Howden SE, Chu L-F, Sontheimer EJ, et al.
Efficient genome engineering in human pluripotent stem cells using Cas9
from Neisseria meningitidis. Proc Natl Acad Sci U S A. 2013;110(39):15644–9.
doi:10.1073/pnas.1313587110.
33. Ran FA, Cong L, Yan WX, Scott DA, Gootenberg JS, Kriz AJ, et al. In vivo
genome editing using Staphylococcus aureus Cas9. Nature.
2015;520(7546):186–91. doi:10.1038/nature14299.
34. Gasiunas G, Barrangou R, Horvath P, Siksnys V. Cas9–crRNA
ribonucleoprotein complex mediates specific DNA cleavage for
adaptive immunity in bacteria.
Proc Natl Acad Sci. 2012;109(39):E2579–86. doi:10.1073/pnas.1208507109.
35. Sternberg SH, Redding S, Jinek M, Greene EC, Doudna JA. DNA
interrogation by the CRISPR RNA-guided endonuclease Cas9. Nature.
2014;507(7490):62–7. doi:10.1038/nature13011.
36. Bétermier M, Bertrand P, Lopez BS. Is non-homologous end-joining really an
inherently error-prone process? PLoS Genet. 2014;10(1):e1004086.
doi:10.1371/journal.pgen.1004086.
37. Sharan SK, Thomason LC, Kuznetsov SG, Court DL. Recombineering: A
Homologous Recombination-Based Method of Genetic Engineering. Nat
Protoc. 2009;4(2):206–23. doi:10.1038/nprot.2008.227.
38. Vasquez KM, Marburger K, Intody Z, Wilson JH. Manipulating the
mammalian genome by homologous recombination. Proc Natl Acad Sci.
2001;98(15):8403–10. doi:10.1073/pnas.111009698.
39. Chu VT, Weber T, Wefers B, Wurst W, Sander S, Rajewsky K, et al. Increasing
the efficiency of homology-directed repair for CRISPR-Cas9-induced precise
gene editing in mammalian cells. Nature biotechnology. 2015;33(5):543–8.
doi:10.1038/nbt.3198.
40. Heyer W-D, Ehmsen KT, Liu J. Regulation of homologous recombination in
eukaryotes. Annu Rev Genet. 2010;44:113–39. doi:10.1146/annurev-genet-
051710-150955.
41. Sakuma T, Nishikawa A, Kume S, Chayama K, Yamamoto T. Multiplex
genome engineering in human cells using all-in-one CRISPR/Cas9 vector
system. Sci Rep. 2014;4:5400. doi:10.1038/srep05400.
42. Guo L, Xu K, Liu Z, Zhang C, Xin Y, Zhang Z. Assembling the Streptococcus
thermophilus CRISPR array for multiplex DNA targeting. Anal Biochem.
2015;478:131–3. doi:10.1016/j.ab.2015.02.028.
43. Ma Y, Shen B, Zhang X, Lu Y, Chen W, Ma J, et al. Heritable multiplex
genetic engineering in rats using CRISPR/Cas9. PLoS One. 2014;9(3):e89413.
doi:10.1371/journal.pone.0089413.
44. Cobb RE, Wang Y, Zhao H. High-Efficiency Multiplex Genome Editing of
Streptomyces Species Using an Engineered CRISPR/Cas System. ACS synthetic
biology. 2014. doi:10.1021/sb500351f.
45. Xing HL, Dong L, Wang ZP, Zhang HY, Han CY, Liu B, et al. A CRISPR/Cas9
toolkit for multiplex genome editing in plants. BMC Plant Biol. 2014;14:327.
doi:10.1186/s12870-014-0327-y.
46. Ryan OW, Skerker JM, Maurer MJ, Li X, Tsai JC, Poddar S et al. Selection of
chromosomal DNA libraries using a multiplex CRISPR system. eLife. 2014;3.
doi:10.7554/eLife.03703.
47. Li P, Estrada JL, Burlak C, Montgomery J, Butler JR, Santos RM, et al. Efficient
generation of genetically distinct pigs in a single pregnancy using multiplexed
single-guide RNA and carbohydrate selection. Xenotransplantation.
2015;22(1):20–31. doi:10.1111/xen.12131.48. Guo X, Zhang T, Hu Z, Zhang Y, Shi Z, Wang Q, et al. Efficient RNA/Cas9-
mediated genome editing in Xenopus tropicalis. Development.
2014;141(3):707–14. doi:10.1242/dev.099853.
49. Yin L, Maddison LA, Li M, Kara N, LaFave MC, Varshney GK et al. Multiplex
Conditional Mutagenesis Using Transgenic Expression of Cas9 and sgRNAs.
Genetics. 2015. doi:10.1534/genetics.115.176917.
50. Jao LE, Wente SR, Chen W. Efficient multiplex biallelic zebrafish genome
editing using a CRISPR nuclease system. Proc Natl Acad Sci U S A.
2013;110(34):13904–9. doi:10.1073/pnas.1308335110.
51. Ousterout DG, Kabadi AM, Thakore PI, Majoros WH, Reddy TE, Gersbach CA.
Multiplex CRISPR/Cas9-based genome editing for correction of dystrophin
mutations that cause Duchenne muscular dystrophy. Nat Commun.
2015;6:6244. doi:10.1038/ncomms7244.
52. Mojica FJM, Díez-Villaseñor C, García-Martínez J, Almendros C. Short motif
sequences determine the targets of the prokaryotic CRISPR defence system.
Microbiology. 2009;155(Pt 3):733–40. doi:10.1099/mic.0.023960-0.
53. DiCarlo JE, Norville JE, Mali P, Rios X, Aach J, Church GM. Genome
engineering in Saccharomyces cerevisiae using CRISPR-Cas systems. Nucleic
Acids Res. 2013;41(7):4336–43. doi:10.1093/nar/gkt135.
54. Guilinger JP, Thompson DB, Liu DR. Fusion of catalytically inactive Cas9 to
FokI nuclease improves the specificity of genome modification. Nat
Biotechnol. 2014;32(6):577–82. doi:10.1038/nbt.2909.
55. Tsai SQ, Wyvekens N, Khayter C, Foden JA, Thapar V, Reyon D, et al. Dimeric
CRISPR RNA-guided FokI nucleases for highly specific genome editing. Nat
Biotechnol. 2014;32(6):569–76. doi:10.1038/nbt.2908.
56. Qi LS, Larson MH, Gilbert LA, Doudna JA, Weissman JS, Arkin AP, et al.
Repurposing CRISPR as an RNA-guided platform for sequence-specific
control of gene expression. Cell. 2013;152(5):1173–83. doi:10.1016/
j.cell.2013.02.022.
57. Maeder ML, Linder SJ, Cascio VM, Fu Y, Ho QH, Joung JK. CRISPR
RNA-guided activation of endogenous human genes. Nat Methods.
2013;10(10):977–9. doi:10.1038/nmeth.2598.
58. Konermann S, Brigham MD, Trevino AE, Joung J, Abudayyeh OO, Barcena C,
et al. Genome-scale transcriptional activation by an engineered CRISPR-Cas9
complex. Nature. 2015;517(7536):583–8. doi:10.1038/nature14136.
59. Gilbert LA, Larson MH, Morsut L, Liu Z, Brar GA, Torres SE, et al. CRISPR-mediated
modular RNA-guided regulation of transcription in eukaryotes. Cell.
2013;154(2):442–51. doi:10.1016/j.cell.2013.06.044.
60. Zhao Y, Dai Z, Liang Y, Yin M, Ma K, He M, et al. Sequence-specific inhibition
of microRNA via CRISPR/CRISPRi system. Sci Rep. 2014;4:3943. doi:10.1038/
srep03943.
61. Gilbert LA, Horlbeck MA, Adamson B, Villalta JE, Chen Y, Whitehead EH,
et al. Genome-Scale CRISPR-Mediated Control of Gene Repression and
Activation. Cell. 2014;159(3):647–61. doi:10.1016/j.cell.2014.09.029.
62. Mizuno S, Dinh TT, Kato K, Mizuno-Iijima S, Tanimoto Y, Daitoku Y, et al.
Simple generation of albino C57BL/6 J mice with G291T mutation in the
tyrosinase gene by the CRISPR/Cas9 system. Mamm Genome. 2014;25
(7–8):327–34. doi:10.1007/s00335-014-9524-0.
63. Shen B, Zhang J, Wu H, Wang J, Ma K, Li Z, et al. Generation of gene-modified
mice via Cas9/RNA-mediated gene targeting. Cell Res. 2013;23(5):720–3.
doi:10.1038/cr.2013.46.
64. Wang H, Yang H, Shivalila Chikdu S, Dawlaty Meelad M, Cheng Albert W,
Zhang F, et al. One-Step Generation of Mice Carrying Mutations in Multiple
Genes by CRISPR/Cas-Mediated Genome Engineering. Cell. 2013;153(4):910–8.
http://dx.doi.org/10.1016/j.cell.2013.04.025.
65. Wu Y, Liang D, Wang Y, Bai M, Tang W, Bao S, et al. Correction of a Genetic
Disease in Mouse via Use of CRISPR-Cas9. Cell Stem Cell. 2013;13(6):659–62.
http://dx.doi.org/10.1016/j.stem.2013.10.016.
66. Fujii W, Kawasaki K, Sugiura K, Naito K. Efficient generation of large-scale
genome-modified mice using gRNA and CAS9 endonuclease. Nucleic Acids
Res. 2013;41(20):e187. doi:10.1093/nar/gkt772.
67. Fujii W, Onuma A, Sugiura K, Naito K. Efficient generation of genome-modified
mice via offset-nicking by CRISPR/Cas system. Biochem Biophys Res Commun.
2014;445(4):791–4. doi:10.1016/j.bbrc.2014.01.141.
68. Gantz VM, Bier E. Genome editing. The mutagenic chain reaction: a method
for converting heterozygous to homozygous mutations. Science.
2015;348(6233):442–4. doi:10.1126/science.aaa5945.
69. González F, Zhu Z, Shi Z-D, Lelli K, Verma N, Li QV, et al. An iCRISPR platform
for rapid, multiplexable, and inducible genome editing in human
pluripotent stem cells. Cell Stem Cell. 2014;15(2):215–26. doi:10.1016/
j.stem.2014.05.018.
Riordan et al. Cell & Bioscience  (2015) 5:33 Page 11 of 1170. Konermann S, Brigham MD, Trevino AE, Hsu PD, Heidenreich M, Cong L,
et al. Optical control of mammalian endogenous transcription and
epigenetic states. Nature. 2013;500(7463):472–6. doi:10.1038/nature12466.
71. Polstein LR, Gersbach CA. A light-inducible CRISPR-Cas9 system for control
of endogenous gene activation. Nat Chem Biol. 2015;11(3):198–200.
doi:10.1038/nchembio.1753.
72. Inui M, Miyado M, Igarashi M, Tamano M, Kubo A, Yamashita S, et al. Rapid
generation of mouse models with defined point mutations by the CRISPR/
Cas9 system. Sci Rep. 2014;4:5396. doi:10.1038/srep05396.
73. Yu Z, Ren M, Wang Z, Zhang B, Rong YS, Jiao R, et al. Highly efficient
genome modifications mediated by CRISPR/Cas9 in Drosophila. Genetics.
2013;195(1):289–91. doi:10.1534/genetics.113.153825.
74. Lin S-C, Chang Y-Y, Chan C-C. Strategies for gene disruption in Drosophila.
Cell Biosci. 2014;4(1):63. doi:10.1186/2045-3701-4-63.
75. Dickinson DJ, Ward JD, Reiner DJ, Goldstein B. Engineering the
Caenorhabditis elegans genome using Cas9-triggered homologous
recombination. Nat Methods. 2013;10(10):1028–34. doi:10.1038/nmeth.2641.
76. Friedland AE, Tzur YB, Esvelt KM, Colaiacovo MP, Church GM, Calarco JA.
Heritable genome editing in C. elegans via a CRISPR-Cas9 system. Nat
Methods. 2013;10(8):741–3. doi:10.1038/nmeth.2532.
77. Mans R, van Rossum HM, Wijsman M, Backx A, Kuijpers NG, van den Broek
M et al. CRISPR/Cas9: a molecular Swiss army knife for simultaneous
introduction of multiple genetic modifications in Saccharomyces cerevisiae.
FEMS Yeast Res. 2015;15(2). doi:10.1093/femsyr/fov004
78. Chang N, Sun C, Gao L, Zhu D, Xu X, Zhu X, et al. Genome editing with
RNA-guided Cas9 nuclease in zebrafish embryos. Cell Res. 2013;23(4):465–72.
doi:10.1038/cr.2013.45.
79. Hwang WY, Fu Y, Reyon D, Maeder ML, Kaini P, Sander JD, et al. Heritable
and precise zebrafish genome editing using a CRISPR-Cas system. PLoS
One. 2013;8(7):e68708. doi:10.1371/journal.pone.0068708.
80. Shao Y, Guan Y, Wang L, Qiu Z, Liu M, Chen Y, et al. CRISPR/Cas-mediated
genome editing in the rat via direct injection of one-cell embryos. Nat
Protoc. 2014;9(10):2493–512. doi:10.1038/nprot.2014.171.
81. Hu X, Chang N, Wang X, Zhou F, Zhou X, Zhu X, et al. Heritable gene-targeting
with gRNA/Cas9 in rats. Cell Res. 2013;23(11):1322–5. doi:10.1038/cr.2013.141.
82. Ma Y, Zhang X, Shen B, Lu Y, Chen W, Ma J, et al. Generating rats with
conditional alleles using CRISPR/Cas9. Cell Res. 2014;24(1):122–5.
doi:10.1038/cr.2013.157.
83. Sato M, Miyoshi K, Nagao Y, Nishi Y, Ohtsuka M, Nakamura S, et al. The
combinational use of CRISPR/Cas9-based gene editing and targeted
toxin technology enables efficient biallelic knockout of the alpha-1,
3-galactosyltransferase gene in porcine embryonic fibroblasts.
Xenotransplantation. 2014;21(3):291–300. doi:10.1111/xen.12089.
84. Tan W, Carlson DF, Lancto CA, Garbe JR, Webster DA, Hackett PB, et al.
Efficient nonmeiotic allele introgression in livestock using custom
endonucleases. Proc Natl Acad Sci U S A. 2013;110(41):16526–31.
doi:10.1073/pnas.1310478110.
85. Whitworth KM, Lee K, Benne JA, Beaton BP, Spate LD, Murphy SL, et al. Use
of the CRISPR/Cas9 system to produce genetically engineered pigs from
in vitro-derived oocytes and embryos. Biol Reprod. 2014;91(3):78.
doi:10.1095/biolreprod.114.121723.
86. Zhou X, Xin J, Fan N, Zou Q, Huang J, Ouyang Z, et al. Generation of
CRISPR/Cas9-mediated gene-targeted pigs via somatic cell nuclear transfer.
CMLS. 2015;72(6):1175–84. doi:10.1007/s00018-014-1744-7.
87. Ni W, Qiao J, Hu S, Zhao X, Regouski M, Yang M, et al. Efficient gene
knockout in goats using CRISPR/Cas9 system. PLoS One. 2014;9(9):e106718.
doi:10.1371/journal.pone.0106718.
88. Feng W, Dai Y, Mou L, Cooper DKC, Shi D, Cai Z. The Potential of the
Combination of CRISPR/Cas9 and Pluripotent Stem Cells to Provide Human
Organs from Chimaeric Pigs. Int J Mol Sci. 2015;16(3):6545–56. doi:10.3390/
ijms16036545.
89. Niu Y, Shen B, Cui Y, Chen Y, Wang J, Wang L, et al. Generation of gene-modified
cynomolgus monkey via Cas9/RNA-mediated gene targeting in one-cell
embryos. Cell. 2014;156(4):836–43. doi:10.1016/j.cell.2014.01.027.
90. Chen Y, Zheng Y, Kang Y, Yang W, Niu Y, Guo X, et al. Functional disruption
of the dystrophin gene in Rhesus Monkey Using CRISPR/Cas9. Human
molecular genetics. 2015;24(13):3764–74. doi:10.1093/hmg/ddv120.
91. Genade T, Benedetti M, Terzibasi E, Roncaglia P, Valenzano DR, Cattaneo
A, et al. Annual fishes of the genus Nothobranchius as a model system
for aging research. Aging Cell. 2005;4(5):223–33. doi:10.1111/j.1474-
9726.2005.00165.x.92. Harel I, Benayoun BA, Machado B, Singh PP, Hu CK, Pech MF, et al. A platform for
rapid exploration of aging and diseases in a naturally short-lived vertebrate. Cell.
2015;160(5):1013–26. doi:10.1016/j.cell.2015.01.038.
93. Zhou Y, Zhu S, Cai C, Yuan P, Li C, Huang Y, et al. High-throughput screening of a
CRISPR/Cas9 library for functional genomics in human cells. Nature.
2014;509(7501):487–91. doi:10.1038/nature13166.
94. Koike-Yusa H, Li Y, Tan EP, Velasco-Herrera Mdel C, Yusa K. Genome-wide
recessive genetic screening in mammalian cells with a lentiviral CRISPR-
guide RNA library. Nat Biotechnol. 2014;32(3):267–73. doi:10.1038/
nbt.2800.
95. Ren Q, Li C, Yuan P, Cai C, Zhang L, Luo GG, et al. A Dual-Reporter System
for Real-Time Monitoring and High-throughput CRISPR/Cas9 Library
Screening of the Hepatitis C Virus. Sci Rep. 2015;5:8865. doi:10.1038/
srep08865.
96. Chen S, Sanjana NE, Zheng K, Shalem O, Lee K, Shi X, et al. Genome-wide
CRISPR Screen in a Mouse Model of Tumor Growth and Metastasis. Cell.
2015;160(6):1246–60. doi:10.1016/j.cell.2015.02.038.
97. Shalem O, Sanjana NE, Zhang F. High-throughput functional genomics
using CRISPR-Cas9. Nat Rev Genet. 2015;16(5):299–311. doi:10.1038/nrg3899.
98. Pichavant C, Aartsma-Rus A, Clemens PR, Davies KE, Dickson G, Takeda S,
et al. Current status of pharmaceutical and genetic therapeutic approaches
to treat DMD. Mol Ther. 2011;19(5):830–40. doi:10.1038/mt.2011.59.
99. Li Hongmei L, Fujimoto N, Sasakawa N, Shirai S, Ohkame T, Sakuma T, et al.
Precise Correction of the Dystrophin Gene in Duchenne Muscular Dystrophy
Patient Induced Pluripotent Stem Cells by TALEN and CRISPR-Cas9. Stem Cell
Rep. 2015;4(1):143–54. doi:10.1016/j.stemcr.2014.10.013.
100. Long C, McAnally JR, Shelton JM, Mireault AA, Bassel-Duby R, Olson EN.
Prevention of muscular dystrophy in mice by CRISPR/Cas9-mediated
editing of germline DNA. Science. 2014;345(6201):1184–8. doi:10.1126/
science.1254445.
101. Zhen S, Hua L, Liu YH, Gao LC, Fu J, Wan DY, et al. Harnessing the clustered
regularly interspaced short palindromic repeat (CRISPR)/CRISPR-associated
Cas9 system to disrupt the hepatitis B virus. Gene Therapy. 2015;22(5):404–12.
doi:10.1038/gt.2015.2.
102. Hu W, Kaminski R, Yang F, Zhang Y, Cosentino L, Li F, et al. RNA-directed
gene editing specifically eradicates latent and prevents new HIV-1 infection.
Proc Natl Acad Sci U S A. 2014;111(31):11461–6. doi:10.1073/
pnas.1405186111.
103. Yin H, Xue W, Chen S, Bogorad RL, Benedetti E, Grompe M, et al. Genome
editing with Cas9 in adult mice corrects a disease mutation and phenotype.
Nat Biotechnol. 2014;32(6):551–3. doi:10.1038/nbt.2884.
104. Blasco RB, Karaca E, Ambrogio C, Cheong TC, Karayol E, Minero VG, et al.
Simple and rapid in vivo generation of chromosomal rearrangements using
CRISPR/Cas9 technology. Cell Rep. 2014;9(4):1219–27. doi:10.1016/
j.celrep.2014.10.051.
105. Jurkowski TP, Ravichandran M, Stepper P. Synthetic epigenetics-towards
intelligent control of epigenetic states and cell identity. Clin Epigenetics.
2015;7(1):18. doi:10.1186/s13148-015-0044-x.
106. Chen B, Gilbert LA, Cimini BA, Schnitzbauer J, Zhang W, Li GW, et al.
Dynamic imaging of genomic loci in living human cells by an optimized
CRISPR/Cas system. Cell. 2013;155(7):1479–91. doi:10.1016/j.cell.2013.12.001.
107. Ma H, Naseri A, Reyes-Gutierrez P, Wolfe SA, Zhang S, Pederson T. Multicolor
CRISPR labeling of chromosomal loci in human cells. Proc Natl Acad Sci
U S A. 2015;112(10):3002–7. doi:10.1073/pnas.1420024112.
108. Fujita T, Fujii H. Efficient isolation of specific genomic regions and identification of
associated proteins by engineered DNA-binding molecule-mediated chromatin
immunoprecipitation (enChIP) using CRISPR. Biochem Biophys Res Commun.
2013;439(1):132–6. doi:10.1016/j.bbrc.2013.08.013.
109. Ablain J, Durand EM, Yang S, Zhou Y, Zon LI. A CRISPR/Cas9 Vector System
for Tissue-Specific Gene Disruption in Zebrafish. Dev Cell. 2015;32(6):756–64.
doi:10.1016/j.devcel.2015.01.032.
110. Albers J, Danzer C, Rechsteiner M, Lehmann H, Brandt LP, Hejhal T, et al. A
versatile modular vector system for rapid combinatorial mammalian
genetics. J Clin Invest. 2015;125(4):1603–19. doi:10.1172/JCI79743.
